51 citations
,
March 2006 in “Bioorganic & Medicinal Chemistry” Newly made nicotinamide compounds could potentially treat cancer.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
February 1999 in “Analytical Sciences” A new antiandrogen compound was made and its detailed three-dimensional shape was described.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
March 2025 in “JAAD reviews.” Bicalutamide can reduce female pattern hair loss, especially in those with certain conditions, but has limited effects on other hair loss types.
24 citations
,
November 1978 in “JAMA” Valproic acid is effective for various seizures, but may cause temporary side effects like drowsiness and stomach issues.
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
April 2022 in “Reactions Weekly” 21 citations
,
August 2002 in “British Journal of Ophthalmology” Drug misuse can cause serious eye infections and other severe side effects.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
10 citations
,
January 2012 in “Case reports in medicine” Diphencyprone can cause unexpected and possibly permanent vitiligo.
11 citations
,
October 1986 in “International Journal of Gynecology & Obstetrics” The contraceptive reduced hair growth and altered hormone levels in hirsute women.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
August 2009 in “Australian Prescriber” Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
36 citations
,
November 1995 in “Clinical endocrinology” Low-dose flutamide helps reduce excessive hair growth and is even more effective with birth control, without bad effects on blood fats.
May 2025 in “Journal of the American Academy of Dermatology” Bicalutamide shows promise for treating female hair loss.
June 2015 in “Reactions weekly” December 2012 in “Reactions weekly” 5 citations
,
March 2021 in “Hepatitis Monthly” Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
July 2021 in “International journal of dermatology, venereology and leprosy sciences” Diphenylcyclopropenone is more effective and has fewer side effects than dinitrochlorobenzene for treating alopecia areata.
June 1993 in “Current opinion in therapeutic patents” Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
1 citations
,
May 2025 in “BMC Cancer” CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
June 2023 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Bicalutamide mesotherapy improved hair density in women with hair loss and was well received.